Age-Related Macular Degeneration (AMD) Disease - Anti VEGF Market

Table of Content

1. INTRODUCTION
   1. Study Assumptions and Market Definition
   2. Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
   1. Market Overview
   2. Market Drivers
      1. Increasing Incidence of Diseases & Surging Geriatric Population
   3. Market Restraints
      1. High Cost of Treatment
      2. Treatment Burden and Compliance Challenges
   4. Market Opportunities
      1. Growing Adoption of Treatment Due to Therapeutic Advancements
   5. Market Trends
      1. Shift Towards Extended Dosing Intervals
      2. Adoption of Combination Therapies
5. MARKET SEGMENTATION
   1. By Product
      1. Eylea
      2. Lucentis
      3. Beovu
   2. By Distribution Channel
      1. Hospitals
      2. Speciality Clinics
      3. Mail Order Pharmacies
   3. By Key Geographic Regions
      1. North America
         1. United States
         2. Canada
         3. Mexico
      2. Europe
         1. Germany
         2. United Kingdom
         3. France
         4. Italy
         5. Spain
         6. Rest of Europe
      3. Asia Pacific
         1. China
         2. Japan
         3. India
         4. Australia
         5. South Korea
         6. Rest of Asia Pacific
      4. Middle East and Africa
         1. GCC
         2. South Africa
         3. Rest of Middle East and Africa
      5. South America
         1. Brazil
         2. Argentina
         3. Rest of South America
6. COMPETITIVE LANDSCAPE
   1. Company Profile
      1. Amgen Inc.
      2. Bayer AG
      3. Biogen
      4. Bausch Health Companies, Inc.
      5. Coherus BioSciences
      6. F. Hoffmann-La Roche Ltd
      7. Novartis AG
      8. Pfizer, Inc.
      9. Regeneron Pharmaceuticals, Inc.
      10. Viatris, Inc.
   2. MARKET OPPORTUNITIES AND FUTURE TRENDS

Frequently Asked Questions

Q.1. What is the projected market value of the global Age-Related Macular Degeneration (AMD) Disease - Anti VEGFmarket?

The global market of Age-Related Macular Degeneration (AMD) Disease - Anti VEGF is projected to reach USD 18.74 Bn by 2033.

Q.2. What is the estimated growth rate (CAGR) of the global Age-Related Macular Degeneration (AMD) Disease - Anti VEGFmarket?

The global Age-Related Macular Degeneration (AMD) Disease - Anti VEGF market has an estimated annual growth rate of 3.9%. 

Q.3. What are the recent trends of Age-Related Macular Degeneration (AMD) Disease - Anti VEGFmarket?

Shift towards extended dosing intervals and adoption of combination therapies are some of the major trends of the market that is projected to boost the market growth in the near future.

Q.4. Which are the top companies to hold the market share in Age-Related Macular Degeneration (AMD) Disease - Anti VEGF?

The major companies profiled in this report include Amgen Inc., Bayer AG, Biogen, Bausch Health Companies, Inc., Coherus BioSciences, F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Viatris, Inc., among others.

Q.5. Which region is estimated to held highest CAGR inAge-Related Macular Degeneration (AMD) Disease - Anti VEGFmarket?

North America is estimated to hold biggest share in the market for Age-Related Macular Degeneration (AMD) Disease - Anti VEGF.